Rizhao Kanghui Bio-pharmaceutical Technology Co., Ltd (Kanghui-Bio), with synthetic biology as the foundation and innovative research and development as the driving force, is committed to the research and development of multi-dimensionally integrated biopharmaceuticals of ‘peptide, nano-antibody and enzyme substitution therapeutics’ as well as the promotion of industrialization. At present, we have established three major technology platforms: ‘Bio-based Peptide Synthesis Platform’, ‘Leading Nanobody Discovery Technology Platform’ and ‘Perfect Recombinant Protein Preparation Technology Platform’. With the technology platform matrix as the core, we have formed a sustainable development of functional product innovation. The company now has a highly internationalized management and research team with comprehensive technical capabilities and rich management experience, with core members coming from world-renowned pharmaceutical companies and first-class research institutes at home and abroad. We have been working in the field of antibody and protein drugs for more than 20 years with outstanding achievements, covering the whole process of drug discovery, biosynthesis and detection from laboratory to pilot production scale.